506879.BO Stock Analysis
50
Avoid
Based on Eyestock quantitative analysis, 506879.BO`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
High score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
Gujarat Themis Biosyn Ltd is a IN-based company operating in Pharmaceuticals industry. The company is headquartered in Mumbai, Maharashtra and currently employs 109 full-time employees. Gujarat Themis Biosyn Limited is an India-based company, which is principally engaged in the manufacturing of pharmaceuticals and medicinal chemical products. The firm is focused on the business of manufacturing and sale of finished active pharmaceutical ingredients (API) products by fermentation process. The firm operates through manufacturing of the bulk drugs segment. Its product portfolio comprises Rifamycin-O and Rifamycin-S. The firm is manufacturing Rifamycin S, which is an intermediate for manufacturing the drug Rifampicin (an Antibiotic used for the treatment of several types of bacterial infections, including tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease.) and Rifamycin O, which is an intermediate for manufacturing the drug Rifaximin (this is an Antibiotic used for treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy). Its research and development division focuses on developing fermentation cultures.